1-8 of 8
obinutuzumab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Clinical Trials & Observations
Jonathan C. Strefford, Malgorzata Nowicka, Chantal E. Hargreaves, Cathy Burton, Andrew Davies, Rosalind Ganderton, Wolfgang Hiddemann, Chisako Iriyama, Wolfram Klapper, Kate V. Latham, Maurizio Martelli, Farheen Mir, Helen Parker, Kathleen N. Potter, Matthew J. J. Rose-Zerilli, Laurie H. Sehn, Marek Trněný, Umberto Vitolo, Christopher R. Bolen, Christian Klein, Andrea Knapp, Mikkel Z. Oestergaard, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2935–2944.
https://doi.org/10.1182/bloodadvances.2020003985
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Clinical Trials & Observations
Malgorzata Nowicka, Laura K. Hilton, Margaret Ashton-Key, Chantal E. Hargreaves, Chern Lee, Russell Foxall, Matthew J. Carter, Stephen A. Beers, Kathleen N. Potter, Christopher R. Bolen, Christian Klein, Andrea Knapp, Farheen Mir, Matthew Rose-Zerilli, Cathy Burton, Wolfram Klapper, David W. Scott, Laurie H. Sehn, Umberto Vitolo, Maurizio Martelli, Marek Trneny, Christopher K. Rushton, Graham W. Slack, Pedro Farinha, Jonathan C. Strefford, Mikkel Z. Oestergaard, Ryan D. Morin, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2945–2957.
https://doi.org/10.1182/bloodadvances.2021004770
Published: 2021
Includes: Supplemental data
Journal Articles

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

Clinical Trials & Observations
Cécile Tomowiak, Stéphanie Poulain, Charles Herbaux, Aurore Perrot, Béatrice Mahé, Pierre Morel, Thérèse Aurran, Olivier Tournilhac, Stéphane Leprêtre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Delphine Nollet, Damien Roos-Weil, Sylvie Chevret, Véronique Leblond
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2438–2446.
https://doi.org/10.1182/bloodadvances.2020003895
Published: 2021
Includes: Supplemental data
Journal Articles

Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma

Cédric Ménard, Delphine Rossille, Joelle Dulong, Tien-Tuan Nguyen, Ilenia Papa, Maelle Latour, Nadège Bescher, Isabelle Bezier, Myriam Chouteau, Thierry Fest, Roch Houot, Franck Morschhauser, Karin Tarte
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2063–2074.
https://doi.org/10.1182/bloodadvances.2020003774
Published: 2021
Includes: Supplemental data
Journal Articles

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA

Clinical Trials & Observations
Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Andrea Knapp, Federico Mattiello, Tina Nielsen, Deniz Sahin, Gila Sellam, Mikkel Z. Oestergaard, Umberto Vitolo, Marek Trněný
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1283–1290.
https://doi.org/10.1182/bloodadvances.2020002690
Published: 2021
Includes: Supplemental data
Journal Articles

Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA

Clinical Trials & Observations
Sarah C. Rutherford, Michael Herold, Wolfgang Hiddemann, Lale Kostakoglu, Robert Marcus, Maurizio Martelli, Laurie H. Sehn, Marek Trněný, Judith Trotman, Umberto Vitolo, Tina Nielsen, Federico Mattiello, Deniz Sahin, Gila Sellam, Peter Martin
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1589–1593.
https://doi.org/10.1182/bloodadvances.2019001261
Published: 2020
Includes: Supplemental data
Journal Articles

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Clinical Trials & Observations
Arnon P. Kater, Sabina Kersting, Yvette van Norden, Julie Dubois, Johan A. Dobber, Clemens H. Mellink, Ludo M. Evers, Fransien Croon-de Boer, John Schreurs, Ellen van der Spek, Hein Visser, Cecile Idink, Shulamiet Wittebol, Mels Hoogendoorn, Sanne H. Tonino, Mehrdad Mobasher, Mark-David Levin
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3566–3571.
https://doi.org/10.1182/bloodadvances.2018019422
Published: 2018
Includes: Supplemental data
Journal Articles

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p

James I. Barnes, Vasu Divi, Adrian Begaye, Russell Wong, Steven Coutre, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert
Journal: Blood Advances
Blood Adv (2018) 2 (15): 1946–1956.
https://doi.org/10.1182/bloodadvances.2017015461
Published: 2018
Includes: Supplemental data